Liver-Directed drug combo shows promise for rare eye cancer
NCT ID NCT04935229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called SD-101, given directly into the liver through a special pressure-enabled infusion, alone or with standard immunotherapy drugs. It was for adults with a rare eye cancer (uveal melanoma) that had spread mainly to the liver. The main goals were to check safety and find the best dose. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA IN THE LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford
Stanford, California, 94305, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.